	US 12,031,976 B2
	Screening method for therapeutic substance for preventing or treating bronchopulmonary dysplasia (BPD)
Yun Sil Chang, Seoul (KR); Won Soon Park, Seoul (KR); Dong Kyung Sung, Seoul (KR); and Young Eun Kim, Gyeonggi-do (KR)
Assigned to SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, Seoul (KR)
Appl. No. 17/050,148
Filed by SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, Seoul (KR)
PCT Filed May 3, 2019, PCT No. PCT/KR2019/005365 § 371(c)(1), (2) Date Jan. 22, 2021, PCT Pub. No. WO2019/212305, PCT Pub. Date Nov. 7, 2019.
Claims priority of application No. 10-2018-0051692 (KR), filed on May 4, 2018; and application No. 10-2019-0052188 (KR), filed on May 3, 2019.
Prior Publication US 2023/0028447 A1, Jan. 26, 2023
Int. Cl. C07H 21/02 (2006.01); G01N 33/50 (2006.01)

CPC G01N 33/5023 (2013.01) [G01N 33/5082 (2013.01)]

3 Claims

1. A screening method for a material for preventing or treating bronchopulmonary dysplasia (BPD), the method comprising the following steps:

(a) treating cells exhibiting bronchopulmonary dysplasia (BPD) conditions with a candidate material;

(b) measuring the expression or activity of formyl peptide receptor 1 (FPR1) in the cells after treatment of the candidate material; and

(c) selecting a material which reduces the expression or activity level of FPR1 compared to a non-treatment group as a material for preventing or treating bronchopulmonary dysplasia (BPD),

wherein the FPR1 gene consists of a nucleic acid sequence represented by any one selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, and

wherein the FPR1 protein consists of an amino acid sequence represented by any one selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.